Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.39 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRE | P78334 | 2/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28536934 | 0.95 | PTGS1 (0.50) | PTGS1PTGS2CYP1A2ENPEPGSTK1 | |
| SCHEMBL28409525 | 0.88 | PTGS1 (0.39) | PTGS1PTGS2CYP1A2ENPEPGSTK1 | |
| SCHEMBL12418610 | 0.79 | MGLL (0.32) | PTGS1PTGS2ALDH1A1TP53POLB | |
| SCHEMBL28258643 | 0.79 | PTGS1 (0.45) | PTGS1PTGS2ENPEPGSTK1ALDH1A1 | |
| SCHEMBL29505890 | 0.79 | KDM4E (0.49) | PTGS1PTGS2CYP1A2ENPEPGSTK1 | |
| SCHEMBL1535510 | 0.78 | LMNA (0.33) | KDM4EALDH1A1TP53POLBHPGD | |
| SCHEMBL5526514 | 0.77 | ALDH1A1 (0.41) | PTGS1PTGS2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL1535492 | 0.77 | MGLL (0.44) | PTGS1PTGS2ALDH1A1POLBHSD17B10 | |
| SCHEMBL18384184 | 0.76 | ALDH1A1 (0.31) | PTGS1PTGS2CYP1A2ALDH1A1POLB | |
| SCHEMBL4287272 | 0.76 | PTGS1 (0.49) | PTGS1PTGS2ENPEPGSTK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729561-A1 | POLYETHYLENE GLYCOL DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025026226-A1 | POLYETHYLENE GLYCOL SMALL MOLECULE DRUG, PREPARATION METHOD THEREFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2025-02-06 | — | — | WO | disclosed |
| WO-2024255854-A1 | POLYETHYLENE GLYCOL DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2024-12-19 | — | — | WO | disclosed |
| CN-119119176-A | Camptothecin derivatives | 伊缪诺金公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-113766954-B | Camptothecin derivatives | 伊缪诺金公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-4316524-A2 | CAMPTOTHECIN DERIVATIVES | ImmunoGen, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-109661229-B | Compounds and compositions for the treatment of cancer | 加利福尼亚大学董事会 | 2022-06-28 | — | — | CN | disclosed |
| CN-114502200-A | Antibody drug conjugates | 深圳康源久远生物技术有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220133711-A1 | CAMPTOTHECIN DERIVATIVES | IMMUNOGEN, INC. | 2022-05-05 | — | — | US | disclosed |
| US-11229639-B2 | Camptothecin derivatives | IMMUNOGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20130178609-A1 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2013-07-11 | — | — | US | disclosed |
| EP-2590989-A2 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS | Universite de Bretagne Occidentale (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-8227555-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120123065-A1 | Hydrolytically Stable Maleimide-Terminated Polymers | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2012004419-A2 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS | UNIVERSITÉ DE BRETAGNE OCCIDENTALE (FR) | 2012-01-12 | — | — | WO | disclosed |
| EP-1578842-B1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | NEKTAR THERAPEUTICS AL CORP (US) | 2009-10-07 | — | — | EP | disclosed |
| US-7432331-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060009590-A1 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS | 2006-01-12 | — | — | US | disclosed |
| EP-1578842-A2 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | Nektar Therapeutics Al, Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004060965-A2 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178609-A1 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS | SGMS2, SGMS1, DEGS1 | PTGS1 3784/4885PTGS2 3474/4885CYP1A2 3671/4885 |
| US-20220133711-A1 | CAMPTOTHECIN DERIVATIVES | TOP2A, TOP2B, PCNA | PTGS1 2344/4885PTGS2 2678/4885CYP1A2 4422/4885 |
| US-11229639-B2 | Camptothecin derivatives | TOP2A, TOP2B, PCNA | PTGS1 2344/4885PTGS2 2678/4885CYP1A2 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.